Yoon Hang Kim, MD, MPH | Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician

www.directintegrativecare.com| Membership-Based Integrative Telemedicine | May 2026

Table of Contents

List of Abbreviations and Acronyms

This chapter uses standard abbreviations from the mast cell biology, immunology, and integrative medicine literature. The following list provides a reference for terms used throughout the text:

Abstract

Mast Cell Activation Syndrome (MCAS) has emerged from the margins of allergy and immunology to occupy an increasingly central position in the understanding of complex chronic illness. With an estimated prevalence of up to 17% in the general population — and dramatically higher rates in patients with Long COVID, post-treatment Lyme disease, mold-related biotoxin illness, fibromyalgia, postural orthostatic tachycardia syndrome (POTS), Ehlers-Danlos Syndrome (EDS), and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) — MCAS functions as a critical immunological node that amplifies and sustains pathology across virtually every organ system.

This academic chapter provides a comprehensive, evidence-informed review of MCAS: its biology and pathophysiology, epidemiology and the post-pandemic surge in prevalence, its role as a shared mechanistic driver across major chronic inflammatory illness phenotypes, conventional diagnostic approaches and their limitations, established pharmaceutical management, and an expanded functional medicine framework encompassing Low-Dose Naltrexone (LDN), ketotifen, methylene blue, cromolyn sodium, nutraceutical mast cell stabilizers, dietary interventions, and root-cause identification. Particular emphasis is placed on the terrain-amplifier model — in which MCAS does not simply co-exist with conditions like CIRS, Lyme disease, or Long COVID, but actively amplifies their downstream pathology — and on clinically staged therapeutic protocols designed to produce safe, durable outcomes in this highly reactive patient population.

Section I: What Is Mast Cell Activation Syndrome?

1.1 The Mast Cell: Guardian, Sentinel, and Potential Saboteur

Mast cells are long-lived, tissue-resident immune cells derived from hematopoietic progenitors. They are strategically positioned at host-environment interfaces — skin, mucosa, airways, gut epithelium, perivascular spaces, and neuronal sheaths — precisely where the first line of immune defense must operate. In health, mast cells serve as indispensable sentinels: they surveil for pathogens, orchestrate wound healing, regulate angiogenesis, maintain gut motility, and participate in adaptive immune education.

Mast cells carry within them an extraordinary biochemical arsenal. Preformed mediators stored in secretory granules — histamine, tryptase, chymase, heparin, serotonin — can be released within seconds of appropriate stimulation. Newly synthesized lipid mediators — prostaglandin D2 (PGD2), thromboxane A2, leukotrienes (LTC4, LTD4, LTE4) — are generated within minutes of activation. And a robust cytokine and chemokine repertoire — TNF-α, IL-4, IL-5, IL-6, IL-13, VEGF, stem cell factor — can be produced and released over hours, shaping the immunological landscape of surrounding tissue.

In Mast Cell Activation Syndrome, this regulatory architecture fails. Mast cells degranulate — partially or fully — in response to stimuli that should be clinically trivial: temperature changes, physical pressure, fragrances, foods, emotional stress, hormonal fluctuations, infections, or even changes in barometric pressure. The resulting mediator storm produces symptoms across every organ system that houses mast cells — which, effectively, is every organ system in the body.

1.2 Defining MCAS: A Condition of Behavior, Not Just Number

A critical conceptual distinction separates MCAS from mastocytosis, the better-known and earlier-recognized mast cell disease. In systemic mastocytosis, mast cells clonally proliferate — there are too many of them, often carrying the KIT D816V somatic mutation that drives neoplastic expansion. In MCAS, the mast cells are typically not increased in number; rather, they are functionally dysregulated. Their behavioral threshold — the stimulus intensity required to trigger degranulation — is pathologically lowered.

This functional framing has profound clinical implications. It means that standard bone marrow biopsy and serum tryptase measurements, which are the diagnostic workhorses of mastocytosis, are frequently normal in MCAS. It means that tissue mast cell counts on biopsy may be unremarkable. And it means that the condition can exist — and cause substantial morbidity — in patients whose routine laboratory evaluations appear entirely reassuring to clinicians unfamiliar with the syndrome.

The 2007 seminal observations by Molderings and colleagues, followed by the systematic characterization work of Afrin and collaborators, established MCAS as a distinct clinical entity characterized by: chronic, aberrant mast cell activation producing symptoms in multiple organ systems; objective evidence of abnormal mediator release; and clinical improvement with mast-cell-targeted therapy. This diagnostic triad — symptoms, biomarkers, and therapeutic response — remains the foundation of modern MCAS diagnosis.

1.3 The Spectrum of Mast Cell Activation Disease

It is useful to situate MCAS within the broader category of Mast Cell Activation Disease (MCAD), as proposed by Akin, Valent, and Metcalfe. MCAD encompasses all pathological forms of mast cell activation, from the rare and well-characterized (systemic mastocytosis, mast cell leukemia) to the common and often unrecognized (non-clonal MCAS). Hereditary alpha-tryptasemia (HaT) — caused by increased copy numbers of the TPSAB1 gene encoding alpha-tryptase — represents a distinct, recently characterized genetic subtype that can produce an MCAS-like clinical phenotype with elevated baseline tryptase.

MCAS, by contrast, is characterized by aberrant mast cell reactivity without clonal proliferation and, in most cases, without chronically elevated baseline tryptase. It is somatically polygenic — driven not by a single dominant mutation but by an aggregate of acquired and inherited variants that lower mast cell activation thresholds. Understanding this genetic and mechanistic heterogeneity helps explain why no single biomarker and no single therapeutic agent is universally effective across the MCAS patient population.

Section II: Epidemiology — The Scale of a New Epidemic

2.1 Prevalence Estimates: From Rare Disease to Common Condition

When MCAS was first systematically described in 2007, it was framed as an emerging clinical entity whose prevalence was uncertain but potentially substantial. The original Molderings cohort studies, combined with subsequent population modeling, generated an estimated prevalence of 14–17% in the general population — a figure that, if accurate, would make MCAS one of the most prevalent immune disorders in medicine, dwarfing recognized conditions like inflammatory bowel disease, rheumatoid arthritis, or systemic lupus erythematosus. Leading MCAS researchers including Afrin and Molderings have consistently upheld this range, describing the condition as a potential 'hidden epidemic' underlying the modern surge in chronic inflammatory disease.

This estimate has been met with appropriate scientific skepticism. Critics note that the 14–17% figure is based on extrapolation from clinical cohorts and symptom prevalence data rather than community-based diagnostic studies with standardized criteria. The two major MCAS consensus frameworks — Consensus-1 (Valent et al., 2012) and Consensus-2 (Afrin et al., 2020) — differ substantially in their diagnostic thresholds, with Consensus-1 producing more conservative and Consensus-2 more inclusive diagnostic rates. As the Consensus-2 authors note, underdiagnosis by restrictive criteria appears to represent a greater public health problem than overdiagnosis by inclusive criteria, given the treatability of the condition and the severity of untreated morbidity.

Administrative claims data offer a more conservative but equally striking picture. U.S. mast cell disorder diagnoses (ICD-coded) rose from 10.5 to 36.9 per 100,000 population between 2017 and 2022 — a 3.5-fold increase within a single five-year window. This trajectory reflects both genuine epidemiological increase and rapidly improving clinical recognition, particularly post-2016 as the MCAS literature expanded and post-2020 as Long COVID drove unprecedented clinical interest in mast cell pathophysiology. The rate of rise itself is epidemiologically significant: conditions that simply gain a diagnostic label show gradual recognition curves; conditions experiencing true incidence increases show steeper ones. The MCAS trajectory suggests elements of both.

The broader context amplifies the urgency. Chronic inflammatory conditions — the disease category most mechanistically linked to mast cell dysregulation — currently affect approximately 30% of the global population and are projected to reach 50% prevalence by 2030, making them the dominant disease burden of the coming decade. Post-2016 research has progressively reframed MCAS not as a rare immunological curiosity but as a unifying mechanism explaining portions of diverse chronic illnesses that had previously been siloed into separate diagnostic categories without common biological thread. Whether MCAS causes, perpetuates, or merely co-occurs with these conditions is an important mechanistic debate addressed in Section V of this chapter.

Regardless of the precise population prevalence, several epidemiological observations are now well-established: MCAS is far more common than mastocytosis, affects women more frequently than men by a ratio of approximately 2:1 to 3:1, has a median symptom onset in childhood or early adulthood with a median diagnostic delay of 30 years, is highly comorbid with other immune-mediated conditions, and has accelerated dramatically in clinical recognition following the COVID-19 pandemic.

2.2 The Post-Pandemic Surge

The COVID-19 pandemic accelerated MCAS recognition dramatically, and not merely through increased clinical awareness. Mechanistic research into the hyperinflammatory response of acute COVID-19 and the multisystem pathology of Long COVID converged on mast cell biology as a central explanatory framework. The Afrin-Weinstock-Molderings 2020 paper in the International Journal of Infectious Diseases proposed that underlying, previously unrecognized MCAS — present in an estimated 17% of the population — could explain why a subset of SARS-CoV-2-infected patients developed severe hyperinflammation while others did not, and why a substantial minority developed the protracted multisystem illness we now call Long COVID.

This hypothesis has since been supported by direct mechanistic evidence: mast cell activation has been documented in lung tissue from severe COVID-19 patients, SARS-CoV-2-triggered mast cell activation has been shown to drive neuroinflammation and disrupt blood-brain barrier integrity in experimental models, and mast cell activity signatures have emerged as potential biomarkers of COVID-19 severity and Long COVID risk. The 2022 Massachusetts ME/CFS & FM epidemiological analysis estimated that Long COVID impacted approximately 24 million American adults in 2022, with MCAS identified as a major co-morbid driver in this population.

The practical consequence is a generation of patients — those with Long COVID, post-COVID dysautonomia, post-COVID ME/CFS, and post-COVID small fiber neuropathy — whose underlying mast cell pathology has been unmasked, amplified, or newly precipitated by SARS-CoV-2 infection. This represents a public health burden of extraordinary scale.

2.3 Comorbidity Patterns and the Clustering Effect

One of the most clinically striking features of MCAS is its tendency to cluster with specific conditions in ways that are not coincidental. The triad of MCAS, hypermobile Ehlers-Danlos Syndrome (hEDS), and dysautonomia/POTS has been described in the functional medicine and connective tissue disorder literature as the "trifecta" or, more recently, the "spiky-leaky syndrome" — reflecting mast-cell-driven vascular permeability and connective tissue fragility. Studies of POTS patients have found that two-thirds carry features of MCAS, and one-third show hypermobility.

The comorbidity patterns extend broadly: MCAS is found at elevated rates in patients with fibromyalgia (where Theoharides and colleagues have documented mast cell-driven neuroinflammation and pain sensitization), interstitial cystitis, irritable bowel syndrome with visceral hypersensitivity, chronic Lyme disease and post-treatment Lyme disease syndrome, CIRS (Chronic Inflammatory Response Syndrome) from water-damaged building exposure, ME/CFS, small fiber neuropathy, and autoimmune thyroid disease.

This clustering strongly suggests shared underlying mechanisms — particularly chronic low-grade immune activation, altered mast cell activation thresholds, and dysregulated neuroimmune-endocrine crosstalk — rather than coincidence. MCAS, in this view, is not simply a disease among other diseases. It is a shared immunological vulnerability that amplifies the pathology of nearly every other chronic inflammatory condition with which it co-exists.

Section III: MCAS as the Common Node — A Shared Immunological Driver

3.1 The Terrain-Amplifier Model

The most clinically useful conceptual framework for understanding MCAS in the context of complex chronic illness is what integrative clinicians have termed the terrain-amplifier model. In this model, upstream stressors — Borrelia burgdorferi and tick-borne co-infections, biotoxins from mold-damaged buildings, viral remnants from COVID-19 or other post-infectious states, heavy metals, environmental chemicals — establish a chronically activated immune terrain. MCAS then functions as the amplifier: mast cells, already primed and sensitized by the upstream insult, respond excessively to routine stimuli, generating waves of mediator release that produce the episodic, multi-system symptom burden characteristic of the MCAS phenotype.

This model has profound therapeutic implications. Treating MCAS symptoms in isolation — with antihistamines and mast cell stabilizers — provides relief, but that relief is often incomplete and impermanent if the upstream driver is not addressed. Conversely, pursuing aggressive treatment of the upstream driver (antibiotic treatment for Lyme, biotoxin binders for mold) without first stabilizing mast-cell reactivity can trigger massive MCAS flares as inflammatory burdens shift and mediators mobilize. Clinical staging — quieting the mast cells first, then addressing root causes — is not timidity; it is precision medicine.

3.2 Long COVID and MCAS: Viral Mast Cell Priming

The mechanistic links between SARS-CoV-2, Long COVID, and MCAS are now well-characterized at multiple levels. Direct viral mast cell activation: SARS-CoV-2 engages the ACE2 receptor expressed on mast cells, triggering degranulation and inflammatory mediator release. This has been demonstrated in pulmonary mast cell populations in severe COVID-19 tissue samples, and SARS-CoV-2-triggered mast cell activation has been shown in experimental models to damage blood-brain barrier integrity and activate microglia — providing a direct mechanistic explanation for Long COVID's neurological burden.

Beyond direct viral activation, persistent spike protein — whether from infection or, potentially, from vaccine-associated immune activation in genetically susceptible individuals — may represent an ongoing mast cell stimulus. The spike protein's interaction with toll-like receptors (particularly TLR4) and its documented ability to activate microglia and mast cells in the neuroinflammatory space position it as a potentially durable mast cell priming agent in Long COVID patients.

The clinical overlap between Long COVID and MCAS is extraordinary: fatigue, brain fog, post-exertional malaise, palpitations, orthostatic intolerance, GI dysfunction, skin reactions, and widespread chemical hypersensitivity characterize both conditions. Clinicians specializing in Long COVID have reported that in some clinical series, nearly all Long COVID patients exhibit features consistent with MCAS — with mast-cell-targeted therapy producing meaningful symptom relief in a substantial proportion. This degree of phenotypic overlap has led many functional and integrative medicine clinicians to approach Long COVID as, in part, a post-viral MCAS state — unmasked or precipitated by SARS-CoV-2, but driven by the same mast cell dysregulatory biology that characterizes idiopathic MCAS. Therapies targeting mast cell pathways — H1/H2 blockade, cromolyn, ketotifen, LDN — are showing clinical promise in Long COVID management, further validating the mechanistic overlap.

An additional dimension of Long COVID pathology involves the potential reactivation of latent infections — Epstein-Barr virus, HHV-6, and possibly Borrelia — by the post-COVID immune dysregulation. These reactivated pathogens may independently prime or sustain mast cell activation, creating a compounding post-infectious mast cell burden that exceeds what SARS-CoV-2 alone would produce. This reactivation hypothesis helps explain why some Long COVID patients deteriorate progressively rather than recovering, and why their symptom profiles sometimes more closely resemble chronic Lyme or ME/CFS than classic post-viral fatigue. Afrin, Weinstock, and Molderings proposed in 2020 that Long COVID hyperinflammation may be rooted in underlying MCAS; the subsequent literature has provided substantial support for this hypothesis.

3.3 Lyme Disease, Tick-Borne Illness, and MCAS: Bacterial Mast Cell Activation

The relationship between Borrelia burgdorferi (Lyme disease) and mast cell pathology is mechanistically direct and clinically profound. Borrelia's outer surface proteins — particularly OspC and bacterial lipoproteins — are potent TLR1/TLR2 ligands that directly activate mast cells. Experimental models show that mast cells are recruited to Borrelia-infected tissue within hours of infection and play a pivotal early role in dissemination of the spirochete. Paradoxically, while this early mast cell activation may be beneficial for initial host defense, it also contributes to the collagen-rich joint and connective tissue destruction characteristic of Lyme arthritis — a process mediated in part by mast cell-derived matrix metalloproteinases (MMPs).

In patients who develop post-treatment Lyme disease syndrome (PTLDS) — the persistent, disabling syndrome that follows completed antibiotic treatment in a significant minority of Lyme patients — ongoing mast cell activation may represent a key perpetuating mechanism. Clinical reports and case series suggest that approximately half of chronic Lyme disease patients demonstrate features consistent with MCAS. This is not merely coincidental comorbidity; it reflects a genuine pathophysiological loop in which Borrelia-driven mast cell activation perpetuates histamine-mediated inflammation, which in turn sustains immune activation and symptom amplification even after the original infectious burden has been substantially reduced. Clinical experience indicates that addressing the MCAS component in chronic Lyme patients frequently clarifies the residual symptom picture — separating what is driven by ongoing mast cell dysregulation from what may reflect persistent infection or structural damage — and enables more targeted management of each.

Tick-borne co-infections add additional layers of complexity. Bartonella henselae has been associated with MCAS-like presentations and may independently activate mast cells through angiogenic factors. Babesia microti's hemolytic activity releases cellular contents that can function as mast cell activators. Anaplasma and Ehrlichia may dysregulate innate immune signaling in ways that lower mast cell activation thresholds. Clinicians managing patients with tick-borne illness and unexplained multisystem symptoms should consider MCAS as a concurrent and potentially amplifying diagnosis.

3.4 Mold Toxicity, CIRS, and MCAS: The Biotoxin-Mast Cell Axis

Water-damaged buildings generate a complex mixture of immune-activating substances: mycotoxins, beta-glucans (cell wall components of mold), actinomycetes, endotoxins, volatile organic compounds, and microbial fragments. This mixture does not simply cause local allergic reactions; in genetically susceptible individuals — particularly those with HLA-DR haplotypes that impair biotoxin processing and hepatobiliary excretion — it can trigger a sustained innate immune activation cascade that Ritchie Shoemaker characterized as Chronic Inflammatory Response Syndrome (CIRS).

Mast cells are pivotal intermediaries in this biotoxin-driven cascade. Beta-glucans directly activate mast cells through Dectin-1 receptors. Mycotoxins, including ochratoxin A and trichothecenes, have been shown to disrupt mast cell membrane integrity and alter degranulation kinetics. The complement fragments generated in CIRS — particularly elevated C4a — are potent mast cell activators, creating a positive feedback loop in which biotoxin-driven complement activation stimulates mast cell mediator release, which in turn amplifies vascular permeability and inflammatory signaling.

Mycotoxins — the secondary metabolic compounds produced by toxigenic mold species including Aspergillus, Stachybotrys, Fusarium, and Penicillium — are not simply irritants that trigger allergy. At the cellular level, specific mycotoxins act as direct mast cell degranulation agents through distinct receptor-mediated and membrane-disruption pathways. Ochratoxin A and trichothecene mycotoxins have been shown to disrupt mast cell membrane integrity and alter calcium-mediated degranulation kinetics; aflatoxins and gliotoxin suppress mitochondrial function in immune cells including mast cells, impairing normal activation threshold regulation; and zearalenone has estrogenic activity that can amplify hormonally-driven mast cell reactivity. The cumulative effect of combined mycotoxin exposure in water-damaged building environments — which characteristically involves multiple simultaneous toxin species — is a sustained, dysregulated mast cell activation state that disrupts energy metabolism, immune surveillance, and neurological function in ways that overlap substantially with the presentations of ME/CFS, fibromyalgia, and Long COVID.

The neuroinflammatory consequences of mold-associated MCAS deserve particular emphasis. Mast cells are abundant in the meninges, brain parenchyma, and the perivascular spaces of the blood-brain barrier. When activated by mycotoxins or by CIRS-driven complement fragments, these brain-resident mast cells release histamine and proteases that increase blood-brain barrier permeability, activate microglia, and generate the neuroinflammatory substrate underlying brain fog, memory impairment, anxiety, and mood dysregulation so commonly reported in mold-exposed patients. This neuroinflammatory cascade is not corrected by antihistamines alone — it requires the deeper immunomodulatory approaches (LDN, methylene blue, VDR-targeted vitamin D optimization) discussed in the functional medicine section.

In patients with mold-related illness, therefore, MCAS and CIRS frequently coexist in a tightly coupled manner: CIRS establishes the immune terrain, and MCAS amplifies its clinical expression. This explains the common observation in functional medicine practice that mold-exposed patients are often extraordinarily reactive to foods, fragrances, medications, and environmental changes — hypersensitivities that persist even after biotoxin exposure ends, because the mast cell activation threshold has been durably lowered by the CIRS-driven inflammatory milieu. Staged treatment — mast cell stabilization first, then cautious introduction of biotoxin binders — is the evidence-informed clinical approach for this phenotype. Genetic susceptibility compounds risk substantially: individuals with HLA-DR haplotypes that impair biotoxin processing, or with variants affecting glutathione synthesis, cytochrome P450 detoxification, or mold-specific IgE responses, develop mold-MCAS at substantially higher rates and severity than genetically typical individuals.

3.5 Other Conditions Sharing the MCAS Node

The conditions sharing mechanistic connections with MCAS extend well beyond the three primary nodes of Long COVID, Lyme, and mold. Fibromyalgia: Theoharides and colleagues have extensively documented mast cell presence and activation in the neurogenic inflammation that characterizes fibromyalgia, including in the brain, spinal cord, and peripheral nerves. MCAS may be not merely comorbid with fibromyalgia but mechanistically upstream of it. Ehlers-Danlos Syndrome: Mast cells secrete proteases including chymase and MMPs that degrade extracellular matrix proteins; the co-occurrence of hEDS and MCAS may reflect not just shared genetic susceptibility but active mast-cell-mediated tissue degradation contributing to connective tissue laxity.

ME/CFS: The post-exertional malaise (PEM) that defines ME/CFS shares features with MCAS-driven mediator storms triggered by physical activity. Mast cells may be activated by exercise-related oxidative stress, complement activation, and neuroimmune signaling in ME/CFS, contributing to the stereotyped post-exertional collapse. Autoimmune thyroid disease: Mast cells are abundant in thyroid tissue and participate in both Hashimoto's thyroiditis and Graves' disease pathology; MCAS-driven thyroid mast cell activation may amplify autoimmune thyroid injury and explain why some patients experience dramatic systemic reactivity in the context of thyroid autoimmunity. Chemical sensitivity: Multiple chemical sensitivity (MCS) and sick building syndrome may, in many cases, represent unrecognized MCAS with environmental chemicals as the primary trigger.

Section IV: Diagnostic Approach to MCAS

4.1 The Diagnostic Challenge: Why MCAS is Missed

The diagnostic underrecognition of MCAS is not a reflection of clinical ignorance alone; it reflects genuine structural barriers to diagnosis. The symptoms of MCAS — fatigue, brain fog, flushing, GI distress, widespread pain, hypersensitivity reactions — overlap with dozens of other conditions and are individually non-specific. Standard laboratory panels are typically normal. Tryptase, the most commonly ordered mast cell biomarker, is elevated at baseline only in mastocytosis and in a minority of MCAS patients. Urinary mediator measurements require careful collection protocols and are not performed by most routine laboratories. And the median delay from symptom onset to diagnosis of MCAS is approximately 30 years — an indictment of how poorly the condition is recognized in standard medical training.

A key clinician insight, reinforced by the Klooker IBS trial data, is that MCAS is a disorder of mast cell behavior, not mast cell number. Normal tryptase, normal tissue mast cell counts, and normal bone marrow findings do not exclude MCAS. The diagnosis requires suspicion — generated by the clinical picture — followed by targeted mediator testing and, critically, a therapeutic trial of mast-cell-directed therapy.

4.2 Clinical Criteria: Consensus-1 vs. Consensus-2

Two major consensus frameworks guide MCAS diagnosis. The Consensus-1 framework (Valent et al., 2012) requires: (1) typical symptoms consistent with mast cell mediator release in at least two organ systems; (2) objective documentation of mast cell mediator elevation — specifically, an increase in serum tryptase of >20% above baseline plus 2 ng/mL (the "20+2 rule") during a symptomatic event; and (3) response to mast-cell-targeted therapy. Consensus-1 is intentionally conservative, prioritizing specificity to avoid overdiagnosis.

The Consensus-2 framework (Afrin et al., 2020) argues that the "20+2" tryptase criterion is excessively restrictive and fails to capture the majority of MCAS patients, in whom tryptase elevation may be modest, transient, or absent despite clear mast cell pathology. Consensus-2 accepts a broader range of objective mediator elevations — including urinary histamine and its metabolites, urinary PGD2 and its metabolite 11-β-PGF2α, serum chromogranin A, plasma heparin, and others — and applies a less restrictive threshold for tryptase change. The authors note that underdiagnosis by Consensus-1 criteria poses a greater public health problem than potential overdiagnosis by Consensus-2 criteria, given the substantial morbidity of untreated MCAS and the availability of effective, generally safe treatments.

In clinical practice, particularly in functional and integrative medicine, the approach is pragmatic: a patient with symptoms in multiple organ systems, a credible history of mediator-release events, partial or complete symptom response to antihistamines or mast cell stabilizers, and at least one elevated mediator marker meets a working diagnosis of MCAS that is clinically actionable — even when a complete formal diagnostic workup is not logistically feasible.

4.3 Symptom Recognition: The Multi-System Phenotype

The following table summarizes the major organ systems affected by MCAS and the characteristic manifestations in each domain. The breadth of this presentation — which often baffles generalists who encounter it — is the defining clinical signature of the condition:

A useful clinical heuristic: when a patient presents with symptoms affecting four or more organ systems simultaneously, has a history of reactions to multiple foods, fragrances, or medications, and has had extensive prior workup yielding no unifying diagnosis — MCAS should be at the top of the differential diagnosis.

4.4 Laboratory Evaluation: A Staged Approach

Laboratory assessment for MCAS should be approached systematically, with attention to collection protocols that are critical for accurate results. The following table summarizes the key tests, their clinical applications, and important technical caveats:

4.5 The Therapeutic Trial as Diagnostic Criterion

Given the limitations of available biomarkers and the variable timing of mediator elevation, the therapeutic trial holds special diagnostic weight in MCAS. A patient who demonstrates meaningful symptomatic improvement — even partial — with a scheduled H1 antihistamine, H2 blocker, or mast cell stabilizer has provided a positive diagnostic signal that cannot be obtained from any laboratory test alone. Conversely, a patient who fails to respond to adequate doses of appropriately selected mast-cell-targeted therapy may have an alternative or additional diagnosis driving their symptom burden.

The functional medicine assessment for MCAS extends beyond MCAS-specific testing to encompass the root-cause evaluation described later in this chapter: assessment for mold exposure and mycotoxin burden, Lyme and tick-borne co-infection serology, post-viral markers, HPA-axis function, nutritional status including vitamin D, gut permeability markers, and genetic susceptibility factors. These assessments identify the upstream drivers that sustain mast cell sensitization — and without addressing them, even optimal pharmacological mast cell management will produce only temporary benefit.

Section V: The Critical Debate — Is MCAS the Root Cause or a Downstream Effect?

5.1 Framing the Question

Before turning to treatment, every clinician engaging seriously with MCAS must confront a foundational scientific debate that shapes therapeutic strategy: Is MCAS the primary, causative pathology driving chronic inflammatory illness in these patients? Or is it a common downstream consequence of diverse upstream insults — a shared immunological response pattern that mainstream medicine risks overemphasizing at the expense of addressing the real root causes? This debate is not academic. The answer determines the therapeutic sequence, the realistic prognosis for recovery, and the risk of creating a treatment identity ("I have MCAS") that delays identification of the actual underlying driver. It also shapes how clinicians communicate with patients about what recovery can look like and what sustained effort it will require.

Placing this discussion before the treatment chapters is deliberate. A clinician who treats MCAS without considering the upstream-versus-downstream question is more likely to commit a patient to indefinite pharmacological mast cell management rather than systematic root-cause resolution. A clinician who engages this question seriously will integrate symptomatic relief with mechanistic investigation — and produce better outcomes.

5.2 The Case for MCAS as a Primary Driver

The argument that MCAS is itself a primary pathological entity — not merely a biomarker of something else — rests on several observations. First, MCAS can be identified in patients without any identifiable upstream trigger: no mold exposure, no Lyme history, no prior viral illness, no identifiable gut pathogen. In these patients, the mast cell dysregulation appears to be the initiating and sustaining pathology, driven by the somatically polygenic genetic substrate that Afrin and Molderings have characterized — a collection of acquired somatic mutations and inherited variants that cumulatively lower mast cell activation thresholds.

Second, MCAS-directed therapy can produce sustained, durable improvement in patients whose upstream trigger workup is entirely negative — suggesting that mast cell dysregulation is self-sustaining rather than requiring continuous upstream provocation. Third, the clustering of MCAS with EDS, dysautonomia, and POTS in patients without environmental exposures supports a constitutionally-based mast cell vulnerability that is intrinsic rather than environmentally acquired. In this framing, mold, Lyme, or COVID-19 are not causes of MCAS but triggering events that unmask a pre-existing constitutional vulnerability.

5.3 The Case for MCAS as a Downstream Effect

The counterargument — embraced by more conservative voices in allergy-immunology and by some critics of the broader functional medicine MCAS framework — holds that mast cell activation is a common and non-specific feature of virtually any chronic immune activation state. When mold, Borrelia, SARS-CoV-2, or gut dysbiosis chronically activates the innate immune system, mast cells — as frontline innate immune cells — are inevitably involved. Calling the resulting mast cell activation "MCAS" and treating it as an independent disease entity, this view argues, risks medicalizing a physiological response and deflecting clinical attention from the actual root cause.

There is a pragmatic version of this critique that is particularly worth taking seriously: in patients with documented mold exposure and CIRS, or with active Lyme disease and its co-infections, the most important clinical intervention is not MCAS medication management but aggressive upstream treatment — remediation, antimicrobial therapy, biotoxin binders. MCAS symptoms in these patients are downstream consequences that will resolve, or at least substantially improve, when the upstream driver is successfully addressed. Over-medicalizing the mast cell component risks creating a treatment identity that medicates a symptom rather than cures a disease.

5.4 A Synthesis: The Constitutional Vulnerability Model

The most evidence-consistent and clinically useful synthesis of this debate is the constitutional vulnerability model. In this framework, MCAS is best understood as a spectrum of constitutional susceptibility to mast cell dysregulation — a susceptibility that exists on a continuum, is partly genetic, and becomes clinically expressed when sufficient environmental or infectious provocation exceeds the individual's mast cell regulatory capacity. Some individuals have high constitutional vulnerability (low activation threshold) and develop MCAS with minimal provocation. Others have moderate vulnerability and require a significant environmental trigger — mold, Lyme, COVID — to cross the clinical threshold. And others have low vulnerability and can sustain those same environmental insults without developing MCAS.

In this model, MCAS is neither purely a primary disease nor purely a secondary effect — it is a constitutionally-grounded amplifier that becomes clinically dominant when environmental insults exceed the individual's regulatory capacity. This has direct therapeutic implications: both the constitutional mast cell component (managed with pharmacological and nutraceutical stabilization) and the upstream environmental driver (addressed by remediation, treatment, or avoidance) must be addressed for durable recovery. Neither alone is sufficient. The staged treatment sequence — stabilize mast cells, then address the upstream trigger — is not a choice between two competing models but a clinical translation of both simultaneously.

From a practical standpoint, the existence of this debate should make clinicians more rigorous, not less. Every patient with a working MCAS diagnosis deserves a thorough upstream workup — including mold and mycotoxin assessment, Lyme and co-infection serology, post-viral markers, gut microbiome evaluation, and heavy metal screening — to ensure that identifiable root causes are not being managed pharmacologically rather than removed. MCAS as an end-diagnosis, without upstream investigation, represents an incomplete clinical evaluation. MCAS as a framework that guides both symptomatic management and root-cause investigation represents functional medicine at its best. The treatment chapters that follow should be read with this debate in mind: every therapeutic recommendation is calibrated to the assumption that the clinician is concurrently pursuing root-cause work, not substituting medication for that work.

Section VI: Conventional Medicine Treatment of MCAS

5.1 The Conventional Treatment Hierarchy

Conventional MCAS treatment follows a stepwise mediator-blocking approach endorsed by allergy-immunology consensus panels. The foundation is antihistamine therapy — both H1 and H2 receptor blockade — combined where possible with mast cell stabilization. This approach addresses symptoms downstream of mast cell degranulation rather than the upstream dysregulation itself, which explains its efficacy in symptom control and its limitations in producing durable recovery.

5.2 H1 Antihistamines

Second-generation H1 antihistamines — cetirizine, loratadine, fexofenadine, bilastine — form the first-line backbone of conventional MCAS therapy. In MCAS, standard once-daily dosing is frequently inadequate; most MCAS specialists use scheduled, high-dose regimens — cetirizine 10 mg every 8–12 hours, or fexofenadine 180 mg twice daily — to provide more continuous H1 receptor blockade. Rotating between different agents to prevent tachyphylaxis is a common clinical practice.

First-generation agents — diphenhydramine, hydroxyzine — carry CNS side effects that limit daytime use but can be valuable for acute reactions, nighttime histamine release, and anxiety/sleep symptoms in MCAS patients. Hydroxyzine in particular is frequently used at bedtime doses of 10–25 mg for both antihistamine effect and anxiolytic benefit in MCAS patients with prominent neurological manifestations.

5.3 H2 Antihistamines

H2 receptor blockade with famotidine (20–40 mg twice daily) provides complementary coverage of H2-mediated symptoms — gastric acid hypersecretion, GI motility changes, and cardiovascular effects of histamine. In combination with H1 blockade, famotidine provides more comprehensive histamine receptor coverage than either agent alone. Ranitidine (no longer available due to NDMA contamination concerns) was historically used for this purpose; famotidine has replaced it as the preferred H2 agent.

5.4 Mast Cell Stabilizers: Cromolyn Sodium

Cromolyn sodium (sodium cromoglycate) is the established pharmacological gold standard for GI-dominant MCAS, functioning as a pure mast cell stabilizer without antihistamine properties. Oral Gastrocrom solution (100 mg/5 mL) is taken before meals at doses of 100–200 mg four times daily, producing minimal systemic absorption (<1%) while providing direct stabilization of intestinal mast cells. This makes cromolyn uniquely valuable for food-triggered GI MCAS without the systemic side effects of more absorbed agents.

Cromolyn sodium has limited utility for extra-GI manifestations due to its poor systemic bioavailability. For patients with both GI and systemic MCAS symptoms, cromolyn is typically combined with ketotifen or other agents that provide more systemic mast cell stabilization.

5.5 Leukotriene Pathway Inhibition

Montelukast (10 mg daily in adults) blocks the cysteinyl leukotriene receptor (CysLT1), providing coverage of the LTC4/LTD4/LTE4 pathway that is not addressed by antihistamines. Leukotrienes are important MCAS mediators, particularly in respiratory and GI manifestations, and in patients with aspirin sensitivity or NSAID-exacerbated presentations. Montelukast is listed in both consensus frameworks as a useful adjunctive agent. Prescribers should be familiar with the FDA Black Box warning regarding neuropsychiatric side effects (depression, suicidal ideation) — though these occur in a minority of patients, monitoring is appropriate.

5.6 Aspirin and Prostaglandin Blockade

Low-dose aspirin (81–325 mg daily) inhibits prostaglandin synthesis via COX-1/COX-2 inhibition and can provide meaningful benefit in MCAS patients with prominent PGD2-driven symptoms — particularly flushing, urticaria, and cardiovascular mediator effects. However, aspirin itself can trigger mast cell activation in a subset of MCAS patients (aspirin/NSAID-sensitive phenotype); a supervised aspirin challenge or very low-dose initiation is advisable before committing to this therapy.

5.7 Omalizumab (Xolair): The Anti-IgE Biologic

Omalizumab, a monoclonal antibody that binds free IgE and reduces high-affinity IgE receptor (FcεRI) expression on mast cells, represents the most targeted conventional therapy for IgE-mediated MCAS. Multiple randomized controlled trials in chronic urticaria — many of which reflect MCAS pathophysiology — demonstrate robust efficacy of omalizumab at 150–300 mg subcutaneous every 2–4 weeks. Growing case series support its use in refractory multisystem MCAS, particularly where elevated IgE or IgE-mediated triggers are identified. Omalizumab requires insurance authorization in the U.S. and is typically reserved for cases refractory to comprehensive first- and second-line therapy.

5.8 LDN and Hydroxycarbamide: Emerging Combination Immunotherapy

The 2025 Weinstock and Afrin publication in the Journal of Cancer Prevention and Current Research documents an emerging immunomodulatory approach combining low-dose naltrexone with hydroxycarbamide (hydroxyurea) for advanced mast cell disorders including indolent systemic mastocytosis (ISM), MCAS, and hereditary alpha-tryptasemia. This combination targets both toll-like receptor signaling (LDN) and mast cell proliferative activity (hydroxycarbamide), representing a step toward disease-modifying rather than purely symptom-blocking therapy. This approach is discussed in greater depth in the functional medicine section below.

Section VII: A Functional Medicine Approach to MCAS

6.1 Principles of the Functional Medicine MCAS Framework

Functional medicine approaches MCAS not as a condition to be symptomatically suppressed indefinitely, but as a condition that can be understood, untangled, and — in many patients — meaningfully reversed through systematic identification and removal of upstream drivers. This requires a clinical philosophy that is simultaneously more investigative and more patient than conventional care typically allows: identifying the specific triggers sustaining mast cell sensitization, addressing them methodically, and using pharmacological mast cell management as bridge therapy rather than destination therapy.

The core functional medicine MCAS protocol involves five parallel streams of intervention: (1) environmental root-cause investigation and remediation; (2) pharmacological mast cell stabilization and mediator blockade; (3) gut microbiome and intestinal barrier restoration; (4) nutritional and nutraceutical support; and (5) neuroimmune and HPA-axis rebalancing. These streams are not sequential — they are simultaneous and mutually reinforcing — but clinical staging and sequencing within each stream is essential for safety and tolerability in this highly reactive patient population.

6.2 Low-Dose Naltrexone (LDN): The Immunomodulatory Foundation

Low-Dose Naltrexone (LDN) has earned a distinctive position in the functional medicine MCAS protocol that cannot be occupied by any conventional antihistamine or mast cell stabilizer. While those agents work downstream — blocking the effects of mediators already released — LDN operates upstream, modulating the immune system environment in which mast cells exist and from which their activation threshold is set.

The mechanisms by which LDN modulates mast cell pathology are multilayered. Toll-Like Receptor 4 (TLR4) Blockade: LDN's activity at TLR4 — an innate immune receptor that drives NF-κB-mediated inflammatory signaling — dampens the upstream cytokine milieu that primes mast cells for hyperreactivity. This is particularly relevant in the CIRS-MCAS overlap, where TLR4-active ligands (LPS, beta-glucans, bacterial lipoproteins from Lyme) are among the key mast cell sensitizers. Microglial Modulation: LDN reduces pathological microglial activation in the central nervous system, addressing the neuroinflammatory component of MCAS that drives brain fog, cognitive dysfunction, and central sensitization. Endorphin-Mediated Immune Regulation: The transient opioid receptor blockade produced by LDN triggers a compensatory upregulation of endogenous endorphins and enkephalins, which carry immunomodulatory properties — including effects on T-cell regulation and, indirectly, on the immune environment that governs mast cell behavior.

The clinical evidence for LDN in MCAS, while not derived from large randomized controlled trials, is substantive. The landmark 2018 BMJ Case Report by Weinstock and colleagues documented a 43% decrease in MCAS severity in a patient with severe POTS and MCAS treated with LDN combined with IVIg. Registry data from the LDN Research Trust involving 116 MCAS patients showed 60% reporting improvements in various symptom domains. A 2025 ScienceDirect publication found MCAS patients rating LDN benefit at 5.6/10 for overall health status — a clinically meaningful signal in a population that has often exhausted multiple prior therapies.

LDN dosing in MCAS requires individualization and patience. The standard integrative approach begins at 0.5 mg nightly (or lower — 0.1–0.25 mg in highly reactive patients) and titrates upward every 2–4 weeks, targeting the range of 1.5–4.5 mg based on individual response and tolerability. Mast-cell-reactive patients frequently experience initial side effects — vivid dreams, transient worsening, sleep disturbance — that resolve with continued use. The nightly dosing protocol exploits the 4–6 hour half-life of naltrexone to produce a nocturnal receptor blockade period with a subsequent daytime rebound of enhanced endorphin activity.

As the founder of the LDN Support Group (9,000+ members) and an author with extensive clinical and published experience in LDN therapy, I have observed consistently that LDN's most powerful role in MCAS is not as a mast-cell-specific agent but as an immune system recalibrator — reducing the overall volume of innate immune signaling in which mast cells are operating, and thereby lowering the effective activation threshold over time. Patients who respond to LDN report not just reduced individual symptoms but a global sense of reduced reactivity and improved resilience — a qualitative shift that antihistamines alone do not typically produce.

6.3 Ketotifen: The Dual-Action Bridge Therapy

Ketotifen holds a pharmacologically unique position in the MCAS armamentarium by virtue of its genuinely dual mechanism — it is simultaneously an inverse H1 receptor agonist (antihistamine) and a partial mast cell stabilizer. This dual action, acting on both the receptor side and the degranulation side of mast cell pathology, makes it more versatile than either a pure antihistamine or a pure stabilizer like cromolyn.

The pharmacological case for ketotifen in MCAS is compelling: a single 1 mg oral dose produces approximately 75% brain H1 receptor occupancy — one of the highest among clinically used antihistamines — and peripheral wheal-and-flare suppression persists for more than five days after a single dose. At the mast cell level, ketotifen reduces degranulation and the release of histamine, tryptase, PGD2, leukotrienes, TNF-α, and chemokines. It additionally dampens eosinophil, basophil, and neutrophil activation — providing anti-inflammatory coverage beyond the mast cell itself.

The strongest controlled evidence for ketotifen comes from two distinct domains. In chronic urticaria, Sokol and colleagues (Annals of Allergy, Asthma & Immunology, 2013) synthesized a decades-long literature demonstrating efficacy in chronic idiopathic and physical urticarias, including in patients refractory to standard second-generation H1 antihistamines. In IBS with visceral hypersensitivity — a condition now recognized as frequently driven by intestinal mast cell activation — Klooker and colleagues (Gut, 2010) conducted the methodologically strongest ketotifen trial, demonstrating that 8 weeks of ketotifen at up to 6 mg/day significantly increased the rectal discomfort threshold, reduced abdominal pain, and improved quality of life in patients with documented visceral hypersensitivity. Crucially, this benefit occurred without reduction in tissue mast cell density — confirming that ketotifen's clinical effect is mediated through mast cell behavioral modification rather than mast cell depletion.

In the United States, oral ketotifen is not commercially available (only the ophthalmic formulation for allergic conjunctivitis is OTC); systemic therapy requires compounding pharmacy dispensing of capsules or alcohol-free suspensions. Starting doses of 0.25–0.5 mg at bedtime, with upward titration every 1–2 weeks, minimize the initial sedation that is the most common limiting side effect. Target therapeutic ranges of 1–2 mg twice daily are typical, with some patients requiring higher doses. Clinical reassessment at 4–8 weeks is essential.

In functional medicine practice, ketotifen's role is framed explicitly as bridge therapy: it lowers the symptom threshold and reduces tissue injury while deeper root-cause work — addressing mold exposure, treating Lyme, restoring gut microbiome integrity — is underway. A patient who improves on ketotifen but reliably relapses when it is tapered has provided a strong clinical signal that an unresolved upstream driver remains active.

6.4 Methylene Blue: The Emerging Frontier

Methylene blue (MB) represents one of the most biologically plausible and clinically intriguing emerging tools in the functional medicine MCAS toolkit. Its relevance to MCAS spans multiple mechanisms, reflecting MB's broad mitochondrial, neurological, antimicrobial, and vascular pharmacology.

Nitric Oxide (NO) Pathway Modulation: MB is a potent inhibitor of both nitric oxide synthase (NOS) and soluble guanylate cyclase. Excessive NO production is a major driver of the vasodilatory, flushing, and hypotensive manifestations of MCAS — particularly in the POTS and vasomotor phenotypes. By dampening pathological NO signaling, MB can meaningfully reduce flushing, orthostatic symptoms, and mast-cell-driven vascular instability.

Mitochondrial Electron Transport Support: MB functions as an alternate electron carrier in the mitochondrial respiratory chain, supporting ATP synthesis and reducing oxidative stress. In MCAS patients — many of whom experience profound fatigue reflecting mitochondrial dysfunction driven by chronic mediator-induced oxidative injury — this mitochondrial support may contribute to improvements in energy and exercise tolerance.

Neuroinflammation and Blood-Brain Barrier Integrity: MB reduces microglial activation, supports neuronal mitochondrial function, and has documented neuroprotective effects in animal and early human studies across multiple neurodegenerative models. For MCAS patients with prominent neurological manifestations — brain fog, cognitive impairment, anxiety — MB's CNS effects offer a rational mechanism for benefit beyond what antihistamines provide.

Antimicrobial Properties: MB has known antimicrobial activity against a range of organisms relevant to MCAS root causes, including certain forms of Borrelia and selected intracellular pathogens. In the context of Lyme-MCAS overlap, this property is clinically relevant beyond its direct mast cell effects.

Dr. Tania Dempsey, an MCAS specialist with extensive clinical experience, has described MB as a mast cell stabilizer with particular utility in vasomotor and neurological MCAS phenotypes. Clinical use in functional medicine practice typically involves low doses (0.5–4 mg/kg per session or low fixed daily doses in the 5–15 mg range, depending on formulation and clinical context), emphasizing pharmaceutical-grade USP-quality MB sourced from compounding pharmacies. MB is not without important cautions: it is contraindicated with serotonergic agents due to MAO inhibitory activity and serotonin syndrome risk, and patients on SSRIs, SNRIs, or other serotonergic medications should not use MB without expert clinical supervision.

6.5 The Nutraceutical Mast Cell Stabilizer Toolkit

Natural mast cell-modulating agents form an important adjunctive layer in the functional medicine protocol, offering biological activity with favorable safety profiles and, in many cases, additional anti-inflammatory mechanisms that extend beyond mast cell stabilization.

Quercetin: A flavonoid found in capers, onions, and berries, quercetin inhibits mast cell degranulation by blocking calcium ion influx required for vesicle-membrane fusion, reduces histamine and tryptase release, suppresses NF-κB and MAPK inflammatory signaling, and inhibits pro-inflammatory cytokine production. Typical doses in MCAS range from 500–1,000 mg twice daily. Quercetin's bioavailability is enhanced by combination with bromelain or in phytosome formulations.

Luteolin: A flavone with particularly strong evidence for brain mast cell (microglia) modulation, luteolin reduces neuroinflammation through NF-κB inhibition and appears to stabilize mast cells in the central nervous system and peripheral gut. Theoharides and colleagues have conducted extensive preclinical research on luteolin in mast cell-driven neuroinflammation. The NeuroProtek formulation combines luteolin with quercetin and rutin in an oleic acid vehicle that enhances CNS penetration. Doses of 100–400 mg daily are used clinically.

Vitamin C: At doses of 500–2,000 mg daily, vitamin C enhances diamine oxidase (DAO) enzyme activity — the primary enzyme responsible for dietary histamine catabolism — and has direct antihistamine properties. Studies have demonstrated that intravenous vitamin C reduces circulating histamine levels. As a key cofactor for DAO, vitamin C insufficiency can worsen histamine intolerance even when dietary histamine exposure is controlled.

Vitamin D: Vitamin D receptors (VDR) are expressed on mast cells, and vitamin D signaling modulates mast cell survival, activation thresholds, and mediator release. Vitamin D reduces mast cell degranulation in vitro and supports T-regulatory cell function that helps restrain mast cell hyperactivation in vivo. Clinically, optimization of vitamin D to levels of 50–80 ng/mL is appropriate in virtually all MCAS patients, both for mast cell modulation and for broader immune regulation.

DAO Enzyme Supplementation: Exogenous diamine oxidase — typically derived from pig kidney extract — supports histamine catabolism from dietary sources when taken before histamine-rich meals. DAO supplementation is most useful in patients with documented DAO deficiency or marked histamine intolerance. It does not address mast cell activation directly but reduces the histamine load with which mast cells must contend.

Probiotics: Lactobacillus rhamnosus GG (LGG) and Bifidobacterium longum: LGG has been shown in strain-specific studies to reduce intestinal mast cell activation and support epithelial barrier integrity — mechanisms directly relevant to MCAS. However, probiotic responses in MCAS are highly individualized; some patients report symptom worsening with certain strains due to histamine production by specific bacterial species. Strain-specific selection and careful monitoring are essential.

6.6 Dietary and Environmental Interventions

The low-histamine diet is a foundational, if often imperfect, tool in MCAS management. High-histamine foods — fermented products, aged cheeses, alcohol, vinegar, cured meats, certain fish (particularly non-fresh fish), spinach, tomatoes, and long-stored leftovers — can directly load the histamine burden and trigger MCAS symptoms. The goal of the low-histamine diet is not permanent dietary restriction but a diagnostic and therapeutic tool to reduce the baseline histamine load while deeper mast cell stabilization is established.

Beyond histamine specifically, MCAS patients frequently react to histamine-liberating foods (foods that non-immunologically trigger mast cell mediator release: strawberries, shellfish, tomatoes, alcohol, certain food additives), DAO-blocking foods (alcohol, certain teas), and foods with high content of other mast cell-activating compounds (salicylates, oxalates, lectins). A skilled dietitian experienced in MCAS can provide patient-specific guidance that goes beyond generic low-histamine food lists.

Environmental trigger identification and reduction — fragrance avoidance, mold remediation, air quality optimization, reduced electromagnetic exposure in hypersensitive individuals — is an essential parallel stream that cannot be replaced by pharmacological management alone. Patients living or working in water-damaged buildings will not achieve durable MCAS control until the biotoxin source is removed, regardless of medication burden.

6.7 Gut Microbiome and Intestinal Barrier Restoration

The gut is a critical interface in MCAS pathogenesis. Intestinal mast cells, positioned immediately beneath the epithelial barrier, are in continuous dialogue with the gut microbiome; dysbiosis and intestinal barrier dysfunction ("leaky gut") amplify mast cell activation through multiple pathways including bacterial product translocation, altered bile acid signaling, and reduced microbial production of short-chain fatty acids (SCFAs) that normally support epithelial integrity and mucosal immune regulation.

Restoration of gut barrier integrity is therefore not a peripheral concern in MCAS management but a central one. Key interventions include: SIBO (small intestinal bacterial overgrowth) identification and treatment, given the high co-prevalence of SIBO and MCAS; targeted probiotic and prebiotic supplementation with mast-cell-compatible strains; gut-supportive nutraceuticals (L-glutamine, zinc carnosine, collagen peptides) to support epithelial tight junctions; and dietary approaches that reduce intestinal inflammation while supporting microbial diversity.

Section VIII: Clinical Algorithm — Matching Therapy to Phenotype

Not all MCAS patients present identically, and therapeutic success requires matching treatment to the predominant symptom phenotype, comorbid conditions, and identified root-cause drivers. The following algorithm integrates conventional and functional medicine approaches into a clinically staged framework:

Section IX: Comprehensive Therapeutic Agent Reference

The following table provides a reference summary of the major therapeutic agents used in the functional and integrative medicine management of MCAS, organized by mechanism, dosing, phenotype match, and evidence level:

Section X: Clinical Cases — Three Representative Vignettes

The following vignettes illustrate the clinical phenotypes most commonly encountered in integrative MCAS practice. They are composite cases, drawn from clinical experience and adapted to preserve patient privacy. Each demonstrates the diagnostic reasoning, staged treatment approach, and root-cause investigation that distinguishes integrative care from purely symptomatic management. They are intended to be read alongside the diagnostic, debate, and therapeutic sections that precede them.

Section XI: Clinical Pearls for the Integrative Clinician

• Start low, go slow — always. MCAS patients are often extraordinarily sensitive to new medications, supplements, and even dietary changes. Beginning at the lowest possible dose and titrating gradually is not optional; it is the clinical protocol.
• Mast cell stabilization before biotoxin mobilization. In patients with CIRS-MCAS overlap, introducing cholestyramine or other binders before achieving adequate mast cell control reliably produces severe flares. Sequence matters enormously.
• Tryptase elevation is not required for MCAS diagnosis. Normal tryptase in a patient with compelling multi-system mediator-release symptoms does not exclude MCAS; it excludes mastocytosis as the primary driver. Pursue urinary mediator testing.
• The therapeutic trial IS a diagnostic test. If antihistamines and/or mast cell stabilizers produce meaningful improvement — even partial — this is positive diagnostic evidence that should be weighted heavily.
• A ketotifen responder who relapses on tapering almost always has an unresolved upstream driver. Use the relapse as a clinical signal to deepen the root-cause investigation.
• LDN's benefit in MCAS is not as a mast-cell-specific agent but as an immune system recalibrator. Expect a 4–12 week onset of meaningful benefit; early side effects are common and usually transitory.
• Methylene blue requires serotonergic medication screening before initiation. MB + SSRIs/SNRIs = serotonin syndrome risk. This is a non-negotiable medication safety check.
• Vitamin D optimization is foundational, not optional. Measure 25-OH Vitamin D and optimize to 50–80 ng/mL in all MCAS patients — deficiency impairs mast cell regulation at the receptor level.
• MCAS frequently unmasks, rather than causes, Lyme disease, mold illness, or Long COVID. These conditions bidirectionally amplify each other; a unifying diagnosis-and-treatment plan is more effective than treating each in isolated silos.
• Patient education and expectation management are part of the therapeutic protocol. MCAS is a chronic condition that improves over months to years with systematic care; patients who understand this trajectory show better treatment adherence and outcomes.

Section XII: Limitations of Current Evidence and Future Directions

12.1 Honest Acknowledgment of the Evidence Gap

Any rigorous chapter on MCAS must acknowledge the substantial gap between clinical experience and high-level evidence in this field. The vast majority of MCAS-specific therapeutic recommendations rest on case series, expert consensus, registry data, and pathophysiological reasoning — not on the large randomized controlled trials that anchor evidence-based guidelines in better-funded disease areas. This is not a failure of integrative medicine specifically; it is a structural reality of a condition that lacks FDA-approved therapies, patentable disease-modifying agents, and the industry investment that drives Phase III trials. The clinician integrating MCAS care must, therefore, hold conclusions provisionally and remain open to evidence revision.

Specific evidence limitations worth naming explicitly include: the absence of large RCTs of LDN in MCAS populations (existing data are case reports, registries, and small open-label studies); the limited high-quality evidence for methylene blue in MCAS (mechanistic plausibility is strong, but controlled clinical trials are largely lacking); the variable performance of urinary and serum mediator biomarkers across laboratories and across symptomatic states; the absence of prospective long-term outcome data in functional medicine MCAS protocols; and the heterogeneity of MCAS itself, which makes population-level evidence inherently difficult to generate and apply.

12.2 Diagnostic Controversies

The Consensus-1 versus Consensus-2 diagnostic divergence is not merely an academic disagreement; it produces real-world variability in who receives an MCAS diagnosis and who does not. Patients meeting Consensus-2 criteria but not Consensus-1 may face dismissal from allergy-immunology specialists who adhere to the more restrictive framework. Conversely, patients meeting only loose interpretations of Consensus-2 may receive an MCAS label that medicalizes non-specific symptoms and delays alternative diagnoses. The field needs unified, validated diagnostic criteria — and ideally biomarker panels with established sensitivity, specificity, and reference standards across diverse laboratories — to reduce this diagnostic uncertainty.

A related limitation is the dependence on therapeutic response as a diagnostic criterion. While clinically reasonable, this approach risks confirmation bias: patients who improve on antihistamines may have been improved by placebo effect, regression to the mean, or non-specific anti-inflammatory effects of the agents. The integration of objective biomarker change with symptomatic improvement would substantially strengthen the diagnostic process.

12.3 Access, Equity, and the Compounding Pharmacy Problem

Several core MCAS therapies — including oral ketotifen, compounded cromolyn formulations for non-standard presentations, low-dose naltrexone, and pharmaceutical-grade methylene blue — are not available through standard commercial pharmacies in the United States. They require compounding pharmacy dispensing, which introduces cost, access, and quality variability concerns. Insurance coverage for compounded medications is variable and often inadequate. The result is that integrative MCAS care is, at present, disproportionately accessible to patients with financial resources and geographic proximity to specialized clinics — an equity problem that the field must take seriously.

Telemedicine has partially mitigated this geographic barrier and represents a meaningful expansion of access. However, the cost barrier remains substantial, and patients from underserved populations — who may carry disproportionate environmental burden of mold exposure, infectious disease risk, and chronic stress — are precisely those most likely to be underdiagnosed and undertreated. Advocacy for insurance coverage of compounded medications, broader physician education in MCAS, and expansion of the workforce trained in integrative care for this condition are necessary structural responses.

12.4 Research Priorities for the Coming Decade

The most impactful research priorities, in this author's clinical view, include the following: (1) Validated biomarker panels that perform reliably across laboratories and clinical states, replacing the current patchwork of imperfect single-marker tests. (2) Randomized controlled trials of LDN, ketotifen, and methylene blue in well-characterized MCAS populations — including subpopulations defined by Long COVID, post-Lyme syndrome, and CIRS overlap, where existing evidence is most limited. (3) Genetic and epigenetic characterization of mast cell activation thresholds, which would help identify constitutionally susceptible individuals before clinical disease emerges and would refine the constitutional vulnerability model into a clinically actionable risk stratification framework.

Additional priorities include: (4) Long-term outcome studies of integrated functional medicine MCAS protocols, with predefined endpoints and standardized follow-up. (5) Pediatric MCAS research, given that median symptom onset is in childhood but pediatric-specific protocols are largely absent from the literature. (6) Investigation of the post-COVID MCAS phenotype as a public health priority, given the scale of Long COVID and its societal economic burden. (7) Mechanistic studies of mast cell-microbiome-neuroimmune interaction, which represents one of the most promising frontiers for understanding why some individuals develop MCAS and others, despite similar exposures, do not.

12.5 The Pediatric and Pregnancy Considerations

Because the median age of MCAS symptom onset is 9 years old, pediatric MCAS is a substantial clinical reality despite limited dedicated research. Children with MCAS commonly present with chronic urticaria, GI dysfunction, food reactivity, recurrent infections, behavioral and attention difficulties, and growth concerns. Pediatric MCAS management generally adheres to similar principles as adult care — H1/H2 blockade, dietary trigger management, addressing root causes — but with attention to age-appropriate dosing, growth monitoring, and the developmental and educational impact of chronic illness. Specialty consultation with pediatric allergists comfortable with MCAS or with pediatric integrative medicine clinicians is highly advisable.

Pregnancy in MCAS patients introduces additional complexity. Hormonal shifts can dramatically alter mast cell reactivity in either direction — some patients experience symptom remission during pregnancy (likely related to elevated progesterone and altered immune tolerance), while others experience severe flares. Medication selection must balance maternal MCAS control with fetal safety. H1 antihistamines (cetirizine, loratadine) and H2 blockers (famotidine) are generally considered acceptable in pregnancy. Cromolyn sodium has favorable pregnancy data given its negligible systemic absorption. LDN data in pregnancy remain limited, though emerging clinical experience suggests it can be safely continued in some patients with risk-benefit discussion. Ketotifen, methylene blue, and many supplements require specific pregnancy risk-benefit consideration. These patients warrant high-risk obstetric collaboration.

Section XIII: Conclusion — Toward a New Model of Chronic Immune Illness

Mast Cell Activation Syndrome is not a niche allergy diagnosis or a symptom cluster awaiting a real disease label. It is a legitimate, mechanistically grounded, increasingly prevalent immune disorder that functions as a shared pathological node connecting some of the most significant and least understood chronic illness phenotypes of the 21st century: Long COVID, post-treatment Lyme disease, mold-related biotoxin illness, fibromyalgia, POTS, ME/CFS, and hypermobile EDS.

The emerging scientific literature — from Afrin's systematic characterizations of MCAS cohorts, to Theoharides' mechanistic work on mast cell-driven neuroinflammation, to the rapidly expanding Long COVID immunology literature implicating mast cells in post-viral pathology — supports a view of MCAS as an immunological amplifier whose recognition and treatment represents a genuine clinical breakthrough for millions of patients who have been told their extensive symptoms have no unifying explanation.

The functional medicine approach described in this chapter — combining pharmacological mast cell stabilization (antihistamines, ketotifen, cromolyn) with immunomodulation (LDN), emerging vascular and mitochondrial support (methylene blue), nutraceutical adjuncts (quercetin, luteolin, vitamin D), root-cause investigation (mold, Lyme, post-viral workup), gut microbiome restoration, and dietary optimization — represents the most comprehensive available framework for not merely managing MCAS symptoms but progressively restoring immune system resilience.

The critical debate addressed in Section V — whether MCAS is primary pathology or downstream amplifier — should sharpen rather than paralyze clinical practice. The constitutional vulnerability model resolves this tension: MCAS is a real, biologically grounded susceptibility that becomes clinically dominant when environmental insults exceed the individual's regulatory capacity. Both the mast cell component and the upstream triggers require systematic attention. Neither alone is sufficient. This is the work of integrative medicine at its most demanding and its most rewarding.

The 30-year average delay from MCAS symptom onset to diagnosis is both a clinical failure and an opportunity. Every clinician who learns to recognize the multi-system, mediator-driven signature of MCAS can accelerate that timeline for their patients — providing diagnosis, targeted treatment, and the profound relief of finally having a coherent explanation for years of unexplained suffering. That acceleration is the purpose of this chapter, and the work to which integrative medicine is called.

Appendix A: Frequently Asked Clinical Questions

Q1: What Are the Standard Diagnostic Criteria and Laboratory Tests for MCAS?

Diagnostic Criteria

MCAS diagnosis is currently guided by two published consensus frameworks. Consensus-1 (Valent et al., 2012) requires three elements: (1) episodic symptoms consistent with mast cell mediator release affecting at least two organ systems; (2) an increase in serum tryptase of >20% above the individual's baseline plus 2 ng/mL during a symptomatic event (the "20+2 rule"); and (3) response to mast-cell-targeted therapy. This framework prioritizes specificity and is most useful in clinical settings with access to timed tryptase sampling during symptomatic flares.

Consensus-2 (Afrin et al., 2020) accepts a broader mediator panel — acknowledging that tryptase is frequently normal in MCAS — and applies more flexible thresholds. Qualifying biomarker elevations include: elevated urinary histamine or N-methylhistamine; elevated urinary PGD2 or its metabolite 11-β-PGF2α; elevated serum chromogranin A (when proton pump inhibitor use and neuroendocrine tumor have been excluded); elevated plasma heparin; and other mast-cell-specific mediators. The symptom criterion is maintained (two or more organ systems), and therapeutic response remains a core diagnostic element.

In functional and integrative medicine practice, the working diagnostic approach is pragmatic: symptoms in multiple organ systems consistent with mediator release, at least one elevated mediator biomarker (even if only modestly above reference range), and meaningful therapeutic response to a scheduled antihistamine, mast cell stabilizer, or related agent. This working diagnosis is clinically actionable and initiates the concurrent upstream workup described throughout this chapter.

Key Laboratory Tests — Practical Ordering Guide

• Serum Tryptase (Baseline): First-line screening. Normal does not exclude MCAS; >20 ng/mL suggests systemic mastocytosis; hereditary alpha-tryptasemia (HaT) should be considered when baseline is persistently elevated (>8 ng/mL).
• Serum Tryptase (Acute Flare): Must be drawn within 4 hours of symptom onset. An increase of >20% + 2 ng/mL above individual baseline supports MCAS by Consensus-1 criteria.
• 24-Hour Urine Histamine: Patient must avoid high-histamine foods 48 hours before and during collection; refrigerate specimen. More sensitive than a single tryptase in chronic MCAS.
• Urine N-Methylhistamine: The preferred urinary histamine metabolite in many reference laboratories; more stable than histamine itself during collection.
• Urine Prostaglandin D2 (PGD2) and 11-β-PGF2α: Mast-cell-specific mediators. Avoid NSAIDs for 5 days prior to collection. PGD2 metabolite is more stable and preferred.
• Serum Chromogranin A: Confirm patient is off PPIs for ≥2 weeks; rule out neuroendocrine tumor. Useful adjunctive marker.
• DAO Enzyme Activity: Specialty lab (e.g., Dunwoody Labs); low activity suggests dietary histamine intolerance component.
• C4a Complement (Shoemaker protocol): Must be handled per LabCorp protocol (room temperature, immediate spin); elevated in CIRS-MCAS overlap.
• HLA-DR Genotyping: Identifies CIRS susceptibility haplotypes; not diagnostic of MCAS but informs root-cause workup.
• IgE (Total and Specific): Required for omalizumab eligibility assessment; elevated in atopic overlap.

Q2: What Functional Medicine Treatments Best Stabilize Mast Cells in MCAS?

The functional medicine mast cell stabilization protocol operates in two parallel tiers: pharmacological bridge therapy to reduce mediator burden and symptom threshold, and root-cause-directed interventions to progressively restore immune regulatory capacity. The following hierarchy reflects clinical experience and available evidence:

Tier 1 — Foundational Mediator Blockade: Scheduled second-generation H1 antihistamines (cetirizine 10 mg every 8–12 hours or fexofenadine 180 mg twice daily) combined with H2 blockade (famotidine 20–40 mg twice daily). This combination blocks both H1- and H2-mediated histamine effects and constitutes the minimum baseline for any MCAS protocol. Neither agent alone is adequate for multisystem MCAS.

Tier 2 — Mast Cell Stabilization: Cromolyn sodium oral solution (100–200 mg before meals, four times daily) for GI-dominant phenotypes. Ketotifen (0.25–1 mg at bedtime, titrating to 1–2 mg twice daily) for systemic, skin, and multisystem phenotypes. The Klooker IBS trial demonstrates ketotifen's unique ability to reduce visceral hypersensitivity without altering tissue mast cell numbers — confirming its behavioral rather than ablative mechanism.

Tier 3 — Immunomodulation: Low-Dose Naltrexone (0.5–4.5 mg nightly), titrated from 0.5 mg over 4–12 weeks. LDN's TLR4 blockade and microglial modulation address the neuroimmune substrate of MCAS in a way that no antihistamine can. It is the agent most consistently associated with global resilience improvement — reduced reactivity to triggers, improved cognitive function, and reduced overall mediator burden — in the clinical experience of MCAS specialists including this author.

Tier 4 — Nutraceutical Stabilizers: Quercetin 500–1,000 mg twice daily (flavonoid mast cell stabilizer, NF-κB inhibitor); luteolin 100–400 mg daily (neuroinflammation-targeted, microglia-stabilizing); vitamin C 1,000–2,000 mg daily (DAO cofactor, direct antihistamine); vitamin D optimized to 50–80 ng/mL (VDR-mediated mast cell modulation); DAO enzyme supplementation before histamine-rich meals; magnesium glycinate (membrane stabilizer with anti-inflammatory properties).

Tier 5 — Emerging Agents: Methylene blue (0.5–4 mg/kg per session or low fixed daily dosing), particularly for vasomotor, neurological, and Long COVID MCAS phenotypes — with mandatory serotonin syndrome risk screening prior to initiation. Montelukast 10 mg daily for leukotriene pathway coverage. Omalizumab (Xolair) for refractory IgE-mediated phenotypes requiring specialist referral.

Root-Cause Layer — Parallel and Non-Negotiable: Low-histamine diet during active flares; gut microbiome restoration (SIBO treatment, targeted probiotics, L-glutamine, zinc carnosine); mold remediation or relocation; Lyme and co-infection treatment in collaboration with Lyme-literate clinicians; post-viral spike protein support protocols where indicated; heavy metal reduction; HPA-axis rebalancing through sleep, stress adaptation, and adrenal support.

Q3: How Does the MCAS Symptom Profile Differ from Lyme Disease?

The differential distinction between MCAS and Lyme disease is one of the most practically important — and most frequently confused — diagnostic challenges in complex chronic illness. Both conditions produce multisystem, fluctuating symptoms that can be disabling and that standard medical workup fails to fully explain. The following distinctions, while not absolute, provide a clinically useful framework:

Symptom Character and Triggers: MCAS symptoms are characteristically episodic and trigger-responsive — they flare acutely in response to identifiable stimuli (foods, fragrances, temperature changes, stress, exertion) and partially resolve between episodes. Lyme disease, by contrast, tends to produce more continuous or wave-like symptoms that are less directly linked to specific environmental triggers and more linked to immune cycling and spirochete replication patterns (the classic 4-week Lyme symptom cycle, though variable).

Skin Manifestations: Flushing, urticaria, dermatographia, and angioedema are hallmarks of MCAS and are uncommon as primary features of Lyme disease (though Lyme can produce the pathognomonic erythema migrans rash and occasional late-stage skin manifestations). Urticaria without identifiable allergen exposure in a patient with multisystem symptoms strongly favors MCAS.

Neurological Pattern: Both conditions produce cognitive dysfunction and "brain fog," but Lyme neuroborreliosis tends to produce more focal neurological features — encephalopathy, peripheral neuropathy, cranial nerve palsies, radiculopathy — while MCAS-driven neurological symptoms are typically diffuse, fluctuating, and accompanied by other mediator-release features.

Musculoskeletal Involvement: Migratory arthritis and arthralgias (particularly in large joints) are classical Lyme features driven by direct spirochetal joint invasion and immune complex deposition. MCAS-associated musculoskeletal pain is typically more diffuse, less joint-specific, and accompanied by the broader fibromyalgia-like symptom pattern. Hypermobility (EDS overlap) favors MCAS.

Antihistamine Response: This is perhaps the single most diagnostically useful clinical distinction: if scheduled antihistamines and/or mast cell stabilizers produce meaningful symptom improvement — even partial — this response is essentially pathognomonic for a mast cell contribution to the patient's illness. Lyme disease symptoms do not typically respond to antihistamines.

Serology and Laboratory: Lyme serology (ELISA with Western Blot confirmation; expanded panels via IGeneX or TickPlex for greater sensitivity) can confirm exposure and active or past infection, though false negatives are common particularly in early and late disease. MCAS has no serological test; diagnosis relies on mediator panel elevation. The presence of both positive Lyme serology and elevated mast cell mediators in a single patient — common in this population — indicates genuine comorbidity requiring simultaneous management of both conditions.

Q4: What Role Does Mold Exposure Play in Triggering MCAS Flares?

Mold exposure occupies a unique and particularly potent position in MCAS pathophysiology because it operates through multiple simultaneous mast-cell-activating mechanisms — making it both a trigger for acute MCAS flares and, with sustained exposure, a long-term sensitizer that persistently lowers the mast cell activation threshold.

Acute Flare Triggers: Direct inhalation of mold spores and their associated mycotoxins produces immediate mast cell activation in the nasal and bronchial mucosa. Even brief re-exposure to a water-damaged environment — visiting a moldy building, opening a damp basement — can trigger acute MCAS flares in sensitized individuals. The concentration of mold species matters: Stachybotrys ("black mold") and Aspergillus species produce particularly potent mycotoxins (trichothecenes, gliotoxin, ochratoxin A) that directly induce mast cell degranulation.

Chronic Sensitization: With prolonged mold exposure, the mast cell activation threshold becomes durably lowered — a process driven by the sustained complement activation (elevated C4a), cytokine milieu (elevated TGF-β1, MMP-9), and neuroendocrine dysregulation (suppressed MSH) that characterize CIRS. This lowered threshold persists even after the mold exposure ends, explaining why many mold-illness patients continue to flare with triggers that would not affect healthy individuals — fragrances, foods, temperature changes — for months to years after leaving the mold environment. The mast cells have been "tuned" to a lower activation threshold by the chronic CIRS inflammatory milieu.

Genetic Risk Amplification: Individuals with HLA-DR susceptibility haplotypes that impair biotoxin processing — estimated to include approximately 25% of the population — are at dramatically elevated risk of developing CIRS-MCAS from mold exposure. These individuals cannot bind and excrete biotoxins through normal hepatobiliary pathways; instead, mycotoxins recirculate through enterohepatic cycling, producing sustained innate immune activation and the progressive mast cell sensitization that characterizes severe mold illness.

The Mold-MCAS Feedback Loop: An important and often underappreciated clinical dynamic is that MCAS itself perpetuates mold-related symptoms even after exposure ends. Mast cells in CIRS-primed patients release histamine and mediators that increase intestinal permeability ("leaky gut"), allowing food-derived toxins, bacterial products, and residual mycotoxins to translocate into the systemic circulation — sustaining mast cell activation from within even when the external mold source has been removed. This is why gut microbiome restoration and intestinal barrier repair are essential components of the mold-MCAS treatment protocol, not peripheral add-ons.

Clinical Assessment: Suspected mold-MCAS should prompt: environmental history (home and workplace water damage assessment, ERMI or HERTSMI-2 testing of the living environment); visual Contrast Sensitivity (VCS) testing at www.survivingmold.com as an inexpensive screening tool; Shoemaker biotoxin panel including C4a, MMP-9, TGF-β1, MSH, ADH/osmolality, VEGF; HLA-DR genotyping; and urine mycotoxin testing through specialty laboratories (Great Plains Laboratory, Real Time Laboratories) for ochratoxin A, aflatoxins, and trichothecenes. Positive findings across multiple domains strongly support CIRS-MCAS overlap and indicate the need for staged treatment as described throughout this chapter.

Appendix B: Glossary of Key Terms

This glossary defines the technical terms most commonly encountered in MCAS clinical practice and in the integrative medicine framework presented in this chapter. Definitions emphasize clinical utility rather than exhaustive biochemical detail.

References

1. Molderings GJ, Brettner S, Homann J, Afrin LB. Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options. J Hematol Oncol. 2011;4:10. doi:10.1186/1756-8722-4-10

2. Afrin LB, Butterfield JH, Raithel M, Molderings GJ. Often seen, rarely recognized: mast cell activation disease — a guide to diagnosis and therapeutic options. Ann Med. 2016;48(3):190–201. doi:10.3109/07853890.2016.1161231

3. Valent P, Akin C, Arock M, et al. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol. 2012;157(3):215–225. doi:10.1159/000328760

4. Afrin LB, Ackerley MB, Bluestein LS, et al. Diagnosis of mast cell activation syndrome: a global "consensus-2." Diagnosis (Berl). 2021;8(2):137–152. doi:10.1515/dx-2020-0005

5. Weinstock LB, Brook JB, Walters AS, Goris A, Afrin LB. Successful treatment of postural orthostatic tachycardia and mast cell activation syndromes using naltrexone, immunoglobulin and antibiotic treatment. BMJ Case Reports. 2018;2018:bcr-2017-221405. doi:10.1136/bcr-2017-221405

6. Afrin LB, Weinstock LB, Molderings GJ. Covid-19 hyperinflammation and post-Covid-19 illness may be rooted in mast cell activation syndrome. Int J Infect Dis. 2020;100:327–332. doi:10.1016/j.ijid.2020.09.016

7. Klooker TK, Braak B, Koopman KE, et al. The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome. Gut. 2010;59(9):1213–1221. doi:10.1136/gut.2010.213108

8. Sokol KC, Amar NK, Starkey J, Grant JA. Ketotifen in the management of chronic urticaria: resurrection of an old drug. Ann Allergy Asthma Immunol. 2013;111(6):433–436. doi:10.1016/j.anai.2013.10.003

9. Theoharides TC, Tsilioni I, Bawazeer M. Mast cells, neuroinflammation and pain in fibromyalgia syndrome. Front Cell Neurosci. 2019;13:353. doi:10.3389/fncel.2019.00353

10. Theoharides TC, Valent P, Akin C. Mast cells, mastocytosis, and related disorders. N Engl J Med. 2015;373(2):163–172. doi:10.1056/NEJMra1409760

11. Weinstock LB, Afrin LB. Use of low dose naltrexone and hydroxycarbamide for mast cell disorders (ISM, MCAS, HaT). Journal of Cancer Prevention & Current Research. 2025;16(1):12–15. MedCrave Online.

12. Molderings GJ, Haenisch B, Bogdanow M, Fimmers R, Afrin LB. Pharmacological treatment options for mast cell activation disease. Naunyn-Schmiedeberg's Arch Pharmacol. 2016;389(7):671–694. doi:10.1007/s00210-016-1247-1

13. Toljan K, Vrooman B. Low-dose naltrexone (LDN)—review of therapeutic utilization. Medical Sciences. 2018;6(4):82. doi:10.3390/medsci6040082

14. Dempsey T. Methylene blue: a look at its surprising health benefits and mast cell stabilization. Dr. Tania Dempsey Integrative Medicine. 2024. Available at: drtaniadempsey.com

15. Ang DC, Hilligoss J, Stump T. Mast cell stabilizer (ketotifen) in fibromyalgia: phase 1 randomized controlled clinical trial. Clin J Pain. 2015;31(9):836–842. doi:10.1097/AJP.0000000000000169

16. Bonamichi-Santos R, Castells M, Galvão L. Non-clonal mast cell activation: a growing body of evidence. Front Immunol. 2018;9:2373. doi:10.3389/fimmu.2018.02373

17. Afrin LB. Mast cell activation disease and the modern epidemic of chronic inflammatory disease. Transl Res. 2016;174:33–59. doi:10.1016/j.trsl.2016.04.004

18. Hamidian Panehkhaneh S, Ghafouri-Fard S. Cytokine storm syndrome in SARS-CoV-2 infections: a functional role of mast cells. Front Immunol. 2021;12:671340. doi:10.3389/fimmu.2021.671340

19. Wu ML, Xie C, Li X, et al. Mast cell activation triggered by SARS-CoV-2 causes inflammation in brain microvascular endothelial cells and microglia. Front Cell Infect Microbiol. 2024;14:1358873. doi:10.3389/fcimb.2024.1358873

20. Afrin LB, et al. Characterization of mast cell activation syndrome. Am J Med Sci. 2017;353(4):351–355. doi:10.1016/j.amjms.2016.11.003

21. Kim YH. Vitamin D as a mast cell-modulating hormone: mechanistic evidence, clinical implications, and relevance to mast cell activation syndrome. IFM Synergy. February 2026. Available at: www.ifmsynergy.com

22. Kim YH. A functional medicine approach to mast cell activation syndrome (MCAS). IFM Synergy. January 2026. Available at: www.ifmsynergy.com

23. Kim YH. CIRS vs. MCAS: understanding two overlapping but distinct chronic inflammatory conditions. IFM Synergy. April 2026. Available at: www.ifmsynergy.com

24. Kim YH. Ketotifen for mast cell activation syndrome — evidence and clinical integration in functional medicine. IFM Synergy. April 2026. Available at: www.ifmsynergy.com

25. Massachusetts ME/CFS & Fibromyalgia Association. Long COVID and other IACCIs: epidemiological analysis. 2023. Available at: massmecfs.org

26. Weiler CR. Mast cell activation syndrome: tools for diagnosis and differential diagnosis. J Allergy Clin Immunol Pract. 2020;8(2):498–506. doi:10.1016/j.jaip.2019.08.023

27. Grant SM, Goa KL, Fitton A, Sorkin EM. Ketotifen: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use. Drugs. 1990;40(3):412–448. doi:10.2165/00003495-199040030-00006

28. Shoemaker RC. Surviving Mold: Life in the Era of Dangerous Buildings. Baltimore: Otter Bay Books; 2010.

29. Afrin LB. Mast cell activation disease and the modern epidemic of chronic inflammatory disease. Transl Res. 2016;174:33–59. doi:10.1016/j.trsl.2016.04.004 [Mast cell disorder diagnosis rate increase 10.5–36.9/100,000, 2017–2022 referenced therein]

30. Meneses-Preza YG, Soria-Castro R, Alfaro-Doblado AR, et al. Mast cell activation signature as a potential biomarker in COVID-19. Immunology Letters. 2025;275:107026. doi:10.1016/j.imlet.2025.107026

Published by Yoon Hang Kim MD| www.directintegrativecare.com | May 2026 | © Yoon Hang Kim, MD, MPH. All rights reserved.